CRISPR Therapeutics
Search results
Jun 26, 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR -based technologies.
Jun 25, 2024 · The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial...
Get the latest Intellia Therapeutics Inc (NTLA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with ...
Jun 26, 2024 · Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad ...
